4//SEC Filing
Klein Pamela M. 4
Accession 0000899243-23-007666
CIK 0001566373other
Filed
Mar 8, 7:00 PM ET
Accepted
Mar 9, 9:18 AM ET
Size
14.8 KB
Accession
0000899243-23-007666
Insider Transaction Report
Form 4
Klein Pamela M.
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2023-03-08−20,000→ 0 totalExercise: $6.88Exp: 2031-06-04→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2023-03-08−20,000→ 0 totalExercise: $3.41Exp: 2032-06-17→ Common Stock (20,000 underlying) - Other
Stock Option (right to buy)
2020-11-20−15,000→ 0 totalExercise: $4.62Exp: 2029-07-09→ Common Stock (15,000 underlying) - Other
Stock Option (right to buy)
2020-11-20−7,500→ 0 totalExercise: $1.60Exp: 2030-06-23→ Common Stock (7,500 underlying)
Footnotes (4)
- [F1]Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)).
- [F2]As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option.
- [F3](Continued from footnote 2) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.
- [F4]Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options were cancelled effective as of November 20, 2020.
Documents
Issuer
F-star Therapeutics, Inc.
CIK 0001566373
Entity typeother
Related Parties
1- filerCIK 0001781017
Filing Metadata
- Form type
- 4
- Filed
- Mar 8, 7:00 PM ET
- Accepted
- Mar 9, 9:18 AM ET
- Size
- 14.8 KB